GenEdit

·Founded 2016

Overview

GenEdit develops next-generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery. GenEdit has developed a novel and unique, non-viral system for CRISPR/Cas9 delivery. The position focuses on the design, testing of new Cas9 delivery vehicles.

Reach GenEdit directly

Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.

Unlock full contacts →

Frequently asked questions about GenEdit

Who are the partners at GenEdit?

Team members listed for GenEdit include Kunwoo Lee (Chief Executive Officer & Co-founder) and Dong Kim (Chief Business Officer).

How do I contact GenEdit?

GenEdit's contact details are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.

Last updated · Source: ConnectSafely investor database